Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice

Brain Research

Volumn 757, Issue 2, 1997, Pages 176-190

  Shen, Ke Fei ^a   Crain, Stanley M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Etorphine; Excitatory opioid receptor antagonist; Naltrexone; Opioid tolerance and dependence; Tail flick assay; Withdrawal jumping assay

Indexed keywords

ETORPHINE; MORPHINE; NALTREXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG TOLERANCE; ETORPHINE; INFUSIONS, PARENTERAL; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NOCICEPTORS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0030945699     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00197-2     Document Type: Article

References (76)

1. Aghajanian, G.K., Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine, Nature, 276 (1978) 186-188.
2. Arts, K.S., Fujimoto, J.M. and Crain, S.M., Inhibition of the antianalgesic action of dynorphin A in mice by cholera toxin, Pharmacol. Biochem. and Behavior, 46 (1993) 623-628.
3. Bentley, K.W. and Hardy, D.G., Novel analgesics and molecular rearrangements in the morphine-thebaine group. III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of n-allylnormorphine and -norcodeine, J. Amer. Chem. Soc., 89 (1967) 3281-3292.
4. Bergman, St.A., Wynn, R.L., Myers, D.E. and Rudo, F.G., Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay, Arch. Int. Pharmacodyn., 291 (1988) 229-237.
5. Berkley, K.J., Sex differences in pain, Behav. Brain Sci., in press.
6. 2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice, J. Pharmacol. Exp. Ther., 277 (1996) 484-490.
7. 2-adrenergic receptors, Mol. Brain Res., 28 (1995) 72-80.
8. Blane, G.F. and Robbie, D.S., Trial of etorphine hydrochloride (M99 Reckitt) in carcinoma pain, preliminary report, Proc. Brit. Pharmacol. Soc., 20 (1970) 252-253P.
9. Blane, G.F. and Robbie, D.S., Compounds of the oripavine series. In Kosterlitz, H.W., Collier, H.O.J., Villareal, J.E. (Eds.) Agonist and Antagonist Actions of Narcotic Analgesic Drugs, Baltimore, Univ. Park Press, 1973, pp. 120-127.
10. Blane, G.F., Boura, A.L.A., Fitzgerald, A.E. and Lister, R.E., Actions of etorphine hydrochloride (M99): A potent morphine-like agent. Brit. J. Pharmacol. Chemother., 30 (1967) 11-22.
11. Blumberg, H. and Dayton, H.B., Naloxone and related compounds. In H.W. Kosterlitz, H.O.J., Collier and J.E. Villareal (Eds.), Agonist and Antagonist Action of Narcotic analgesic Drugs, Baltimore, Univ. Park Press, 1973, pp. 110-119.
12. Brase, D.A., Iwamoto, E.T., Loh, H.H. and Way, E.L., Reinitiation of sensitivity to naloxone by a single narcotic injection in postaddicted mice, J. Pharmacol. Exp. Ther., 197 (1976) 317-325.
13. Casy, A.F. and Parfitt, R.T., Opioid Analgesics: Chemistry and Receptors, Plenum, New York and London, 1986.
14. Crain, S.M. and Shen, K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons, Trends Pharmacol. Sci., 11 (1990) 77-81.
15. Crain, S.M. and Shen, K.-F., After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside, Brain Res., 575 (1992) 13-24.
16. Crain, S.M. and Shen, K.-F., After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition, J. Pharmacol. Exp. Ther., 260 (1992) 182-186.
17. Crain, S.M. and Shen, K.-F., Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: New rationale for improved clinical analgesia and treatment of opiate addiction. In R.S. Repaka and H. Sorer, (Ed.) Discovery of Novel Opioid Medications, NIDA Monograph, U.S. Govt. Print. Office, Washington, D.C., 1995, pp. 234-268.
18. Crain, S.M. and Shen, K.-F., Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment, Proc. Natl. Acad. Sci. USA, 92 (1995) 10540-10544.
19. Crain, S.M. and Shen, K.-F., Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: an in vitro model of 'protracted opioid dependence', Brain Res., 694 (1995) 103-110.
20. Crain, S.M. and Shen, K.-F., Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists, U.S. Patent, No. 5,512,518, U.S. Patent Office, April 1996.
21. Crain, S.M. and Shen, K.-F., Modulatory effect of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence, Neurochem. Res., 21 (1996) 1347-1351.
22. Crain, S.M., Shen, K.-F. and Chalazonitis, A., Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures, Brain Res., 455 (1988) 99-109.
23. Cruciani, R.A., Dvorkin, B., Morris, S.A., Crain, S.M. and Makman, M.H., Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells, Proc. Natl. Acad. Sci. USA, 90 (1993) 3019-3023.
24. 2- adrenergic receptors to two G-proteins with opposing effects, J. Biol. Chem., 267 (1992) 15759-15801.
25. + conductance of DRG neurons and neuroblastoma X DRG neuron hybrid F11 cells, Brain Res., 696 (1995) 97-105.
26. Fillingim, R.B. and Maixner, W., Gender differences in the responses to noxious stimuli, Pain Forum 4 (1995) 209-221.
27. Fujimoto, J.M. and Rady, J.J., Intracerebroventricular physostigmine-induced analgesia: enhancement by naltrexone, β-funaltrexamine and nor-binaltorphimine and antagonism by dynorphin A (1-17), J. Pharmacol. Exp. Ther., 251 (1989) 1045-1052.
28. Gear, R.W., Miaskowski, C., Gordon, N.C., Paul, S.M., Heller, P.H. and Levine, J.D., Kappa-opioids produce significantly greater analgesia in women than in men, Nature Med., 2 (1996) 1248-1250.
29. Gillman, M.A. and Lichtigfeld, F.J., A pharmacological overview of opioid mechanisms mediating analgesia and hyperalgesia, Neurol. Res., 7 (1985) 106-119.
30. Gillman, M.A. and Lichtigfeld, F.J., Naloxone analgesia: an update, Intern. J. Neurosci., 48 (1989) 321-324.
31. Goldstein, A. and Sheehan, P., Tolerance to opioid narcotics. I. Tolerance to the 'running fit' caused by levorphanol in the mouse, J. Pharmacol. Exp. Ther., 169 (1969) 175-184.
32. Gonzalez, J.P. and Brogden, R.N., Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence, Drugs 35 (1988) 192-213.
33. Greeley, J.D., Le, A.D., Poulos, C.X. and Cappell, H., 'Paradoxical' analgesia induced by naloxone and naltrexone, Psychopharmacol., 96 (1988) 36-39.
34. Hamann, S.R. and Sloan, J.W., Influences of age and nociceptive reactivity on the analgesic actions of naltrexone in the rat, Regul. Pept., 54 (1994) 113-114.
35. Heyman, J.S., Mulvaney, S.A., Mosberg, H.I. and Porreca, F., Opioid δ receptor involvement in supraspinal and spinal antinociception in mice, Brain Res., 420 (1987) 100-108.
36. Holmes, B.B. and Fujimoto, J.M., Inhibiting a spinal dynorphin A component enhances intrathecal morphine antinociception in mice, Anesth. Analg. 77 (1993) 1166-1173.
37. Horan, P.J., Mattia, A., Bilsky, E.J., Weber, S., Davis, T.P., Yamamura, H.I., Malatynska, E., Appleyard, S.M., Slaninova, J., Misicka, A., Lipkowski, A.W., Hruby, V.J. and Porreca, F., Antinociceptive profile of biphalin, a dimeric enkephalin analog, J. Pharmacol. Exp. Ther., 26 (1993) 1446-1454.
38. Jaffe, J.H. and Martin, W.R., Opioid analgesics and antagonists, In: Goodman and Gilman's Pharmacological Basis of Therapeutics, 8th Ed., Pergamon, New York, 1990, pp. 485-521.
39. Kayser, V. and Guilbaud, G., Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats, Brain Res., 226 (1981) 344-348.
40. Kayser, V., Besson, J.M. and Guilbaud, G., Analgesia produced by low doses of the opiate antagonist naloxone in arthritic rats is reduced in morphine-tolerant animals, Brain Res., 371 (1986) 37-41.
41. Kosersky, D.S., Harris, R.A. and Harris, L.S., Naloxone-precipitated jumping activity in mice following the acute administration of morphine, Europ. J. Pharmacol., 26 (1974) 122-124.
42. Levine, J.D., Gordon, N.C. and Fields, H.L., Naloxone dose-dependently produces analgesia and hyperalgesia in postoperative pain, Nature, 278 (1979) 740-741.
43. Levine, J.D., Gordon, N.C., Taiwo, Y.O. and Coderre, T.J., Potentiation of pentazocine analgesia by low-dose naloxone. J. Clin. Invest., 82 (1988) 1574-1577.
44. Maldonado, R., Stinus, L., Gold, L.H. and Koob, G.F., Role of different brain structures in the expression of the physical morphine withdrawal syndrome, J. Pharmacol Exp. Ther., 261 (1992) 669-677.
45. Mudge, A.W., Leeman, S.E. and Fischbach, G.D., Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration, Proc. Natl. Acad. Sci. USA, 76 (1979) 526-530.
46. North, R.A., Opioid receptor types and membrane ion channels, Trends in Neurosci., 9 (1986) 114-117.
47. 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation, Cell 67 (1991) 723-730.
48. Poulos, C.X., Knoke, D.M., Le, A.D. and Cappell, H., Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing, Psychopharmacol., 100 (1990) 31-35.
49. Qin, B.-Y., Research advances of dihydroetorphine: from analgesia to detoxification, New Drugs and Clin. Remedies, 12 (1993) 119-123.
50. Schmidt, J.F., Chraemmer-Jorgensen, B., Pedersen, J.E. and Risbo, A., Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine, Anesthesia, 40 (1985) 583-586.
51. Shen, K.-F. and Crain, S.M., Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture, Brain Res., 491 (1989) 227-242.
52. Shen, K.-F. and Crain, S.M., Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors, Brain Res., 525 (1990a) 225-231.
53. Shen, K.-F. and Crain, S.M., Cholera-toxin-B subunit blocks excitatory effects of opioids on sensory neuron action potentials indicating that GMl ganglioside may regulate Gs-linked opioid receptor functions, Brain Res., 531 (1990) 1-7.
54. Shen, K.-F. and Crain, S.M., Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid dependence without tolerance, Brain Res., 597 (1992) 74-83.
55. Shen, K.-F. and Crain, S.M., Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence, Brain Res., 636 (1994) 286-297.
56. Shen, K.-F. and Crain, S.M., Nerve growth factor rapidly prolongs the action potential of mature sensory neurons in culture and this effect requires activation of Gs-coupled excitatory kappa opioid receptors on these cells, J. Neurosci., 14 (1994b) 5570-5579.
57. Shen, K.-F. and Crain, S.M., Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture, Brain Res., 701 (1995) 158-166.
58. Shen, K.-F. and Crain, S.M., Specific N- or C-terminus modified dynorphin and β-endorphin peptides can selectively block functions in sensory neurons and unmask potent inhibitory effects of opioid agonists, Brain Res., 673 (1995) 30-38.
59. Shen, K.-F., Crain, S.M. and Ledeen, R.W., Brief treatment of sensory ganglion neurons with GM1 ganglioside enhances the efficacy of opioid excitatory effects on the action potential, Brain Res., 559 (1991) 130-138.
60. Sofuoglu, M., Sato, J. and Takemori, A.E., Maintenance of morphine dependence by naloxone in acutely dependent mice. J. Pharmacol. Exp. Ther., 254 (1990) 841-846.
61. Suarez-Roca, H. and Maixner, W., Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. J. Pharmacol. Exp. Ther., 264 (1993) 648-653.
62. Suarez-Roca, H. and Maixner, W., Morphine produces a biphasic modulation of substance P release from cultured dorsal root ganglion neurons, Neurosci. Lett., 194 (1995) 41-44.
63. Taiwo, Y.O., Basbaum, A.I., Perry, F. and Levine, J.D., Paradoxical analgesia produced by low doses of the opiate-antagonist naloxone is mediated by interaction at a site with characteristics of the delta opioid receptor, J. Pharmacol. Exp. Ther., 249 (1989) 97-100.
64. Tallarida, R.J. and Murray, R.B., Manual of Pharmacologic Calculation With Computer Programs, 2nd Ed., Springer-Verlag, New York, 1986.
65. Tokuyama, S., Takahashi, M. and Kaneto, H., Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice, Biol. Pharm. Bull., 16 (1993) 774-777.
66. Tokuyama, S., Nakamura, F., Takahashi, M. and Kaneto, H., Physical dependence produced by dihydroetorphine in mice, Biol. Pharm. Bull., 17 (1994) 1056-1059.
67. Uhl, G.R., Childers, S. and Pasternak, G., An opiate-receptor gene family reunion, Trends in Neurosci., 17 (1994) 89-93.
68. Wang, D.X., Liu, Y.S. and Qin, B.Y., Experimental treatment of dihydroetorphine and naloxone on morphine-dependent rats and monkeys, Chinese J. Pharmacol. Toxicol. 6 (1992) 36-40.
69. Way, E.L., Loh, H.H. and Shen, F.H., Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther., 167 (1969) 1-8.
70. Way, E.L. and Loh, H.H., Responsivity to naloxone during morphine dependence, Ann. N.Y. Acad. Sci., 281 (1976) 252-261.
71. Werz, M.A. and Macdonald, R.L., Opioid peptides with differential affinity for μ- and δ-receptors decrease sensory neuron calcium-dependent action potentials, J. Pharmacol. Exp. Ther., 227 (1983) 394-402.
72. Wikler, A., Opioid Dependence, Plenum, New York, 1980.
73. + currents, J. Neurosci. Res., 42 (1995) 493-503.
74. Wu, G., Lu, Z.-H. and Ledeen, R.W., GM1 conversion of a cloned δ opioid receptor from inhibitor to stimulator of adenyl cyclase, J. Neurochem., 64 (1995) S104.
75. Wu, G., Lu, Z.-H. and Ledeen, R.W., Interaction of δ-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode, Mol. Brain Res., 44 (1997) 341-346.
76. Yano, I. and Takemori, A.E., Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine, Res. Commun. Chem. Pathol. Pharmacol., 16 (1977) 721-734.